Zymogenetics, Inc.

University of Washington

State of Oregon

Other

Eileen R Mulvihill

Frederick S Hagen

Khaled M Houamed

Wolfhard Almers

Shinji Yoshitake

J Mark Kinzie

Julie A Saugstad

Thomas P Segerson

Gary L Westbrook

Patrick J O'Hara

Suguru Suzuki

Akira Hashimoto

Yasunori Ikeda

Teruaki Yuzuriha

Bjorn A Nexo

Donald C Foster

A Ashok Kumar

Kurt Pingel

Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.

L-AP4 sensitive glutamate receptors

Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.

G protein coupled glutamate receptors

Oligonucleotide probes to L-AP4 sensitive glutamate receptor sequences

Method for identifying a G protein coupled glutamate receptor agonist

Antibodies to G protein coupled glutamate receptors

A method of producing proteins of interest is disclosed. The method includes the introduction of a first DNA sequence encoding the protein of interest and at least one additional DNA sequence encoding a protein which processes or stabilizes the protein of interest into a eukaryotic host cell. The host cell is subsequently cultured under conditions which allow the DNA sequences to be expressed. Suitable eukaryotic hosts include mammalian cells and yeast cells.

Co-expression in eukaryotic cells

Tissue plasminogen activator analogs containing the growth factor domain of native t-PA, the domain having at least one cysteine residue replaced with another amino acid. The t-PA analogs may further contain a variety of substitutions and/or modifications. Pharmaceutical compositions containing one or more of the t-PA analogs along With a physiologically acceptable carrier or diluent are also disclosed.

Tissue plasminogen activator analogs having modified growth factor

A plasminogen activator comprising a growth factor domain, a kringle domain and a serine protease domain is disclosed. The growth factor domain contains a plurality of substitutions of substantially consecutive amino acids as compared to the growth factor domain of native t-PA, the substitutions resulting in an increase in plasma half-life.

t-PA with growth factor domain substitutions

Method for producing a mammalian G protein coupled glutamate receptor

Zymogens of proteins having fibrinolytic activity are disclosed. The proteins are cleavable by thrombin, the cleavage resulting in the stimulation of fibrinolytic activity. Suitable proteins which may be modified in accordance with the present invention include tissue plasminogen activator, urokinase, and plasminogen variants. The modified molecules are substantially clot-specific, in view of the large amounts of thrombin associated with clots in vivo.

Thrombin-activated tissue plasminogen activators

Tissue plasminogen activator analogs exhibiting greater specificity for fibrin than native t-PA are disclosed. The analogs include the K1 domain of native t-PA replaced with another kringle domain mediating the binding of the analog to fibrin. The kringle contains six cysteine residues. The t-PA analogs may further include a variety of substitutions and modifications. Pharmaceutical compositions containing one or more of the t-PA analogs along with a physiologically acceptable carrier or diluent are also disclosed.

Modified t-PA with kringle-/replaced by another kringle

Growing community of inventors

Seattle, WA, United States of America

Eileen R Mulvihill